Biotech

All Articles

Amgen reports first period 3 gain for $400M dermatitis drug

.Amgen has shared (PDF) the 1st stage 3 information on its $400 million chronic eczema drug, linking...

Biogen, UCB record period 3 lupus succeed after stopping working earlier test

.Biogen and also UCB's bet one's bottom dollar developing into stage 3 astride a failed study aims t...

Aptadir wishes brand-new RNA preventions can turn around challenging cancers

.Italian biotech Aptadir Therapies has released with the assurance that its pipeline of preclinical ...

Wave surfs DMD excellence to regulatory authorities' doors, sending stockpile

.Wave Life Sciences has actually fulfilled its target in a Duchenne muscle dystrophy (DMD) research ...

Sanofi tweezes new CSO coming from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is coming back to the pharma layer, occupying th...

Achilles droplets tissue treatment program, prepares for cutbacks after skipping 'industrial stability' goals

.Achilles Therapeutics has destroyed its approach. The English biotech is actually stopping work on ...

Aligos trumpets phase 2 MASH gain, lowering liver excess fat as much as 46%

.Aligos Therapies is advertising a midstage win in metabolic-dysfunction affiliated steatohepatitis ...

Basilea scores $268M BARDA financing for antifungals, anti-biotics

.Basilea Pharmaceutica's job developing brand new antifungals has obtained a significant improvement...

Capricor sells Europe legal rights to late-stage DMD therapy for $35M

.Having presently gathered up the U.S. civil liberties to Capricor Therapies' late-stage Duchenne mu...

FDA junks adcomm for Applied's unusual disease medicine

.After pushing back the selection meeting for Applied Rehabs' metabolic ailment medicine govorestat,...